HY-P703150 Search Results


recombinant fst protein  (MedChemExpress)
90
MedChemExpress recombinant fst protein
FIGURE 5 | Overexpression of <t>FST</t> reduces cardiac fibrosis by inhibiting the activation of the TGF-β–Smad3 pathway in vivo and in vitro. Quantitative real-time PCR analysis of TGF-β1, activin A, and TGF-β3 mRNA transcription [(A–C), n≥4] and p-Smad3 and Smad3 protein expression in each group [(D), n 4]. In vitro, NIH3T3 cells were treated with or without high glucose (30 mM), <t>recombinant</t> FST protein (10 ng/ml), and TGF-β1 (20 μM). Protein expression of COL1, COL3, p-Smad3, and Smad3 with different treatments [(E–G), n 3]. *p< 0.05; **p< 0.01; ***p<0.001.
Recombinant Fst Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant fst protein/product/MedChemExpress
Average 90 stars, based on 1 article reviews
recombinant fst protein - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


FIGURE 5 | Overexpression of FST reduces cardiac fibrosis by inhibiting the activation of the TGF-β–Smad3 pathway in vivo and in vitro. Quantitative real-time PCR analysis of TGF-β1, activin A, and TGF-β3 mRNA transcription [(A–C), n≥4] and p-Smad3 and Smad3 protein expression in each group [(D), n 4]. In vitro, NIH3T3 cells were treated with or without high glucose (30 mM), recombinant FST protein (10 ng/ml), and TGF-β1 (20 μM). Protein expression of COL1, COL3, p-Smad3, and Smad3 with different treatments [(E–G), n 3]. *p< 0.05; **p< 0.01; ***p<0.001.

Journal: Frontiers in pharmacology

Article Title: Follistatin Attenuates Myocardial Fibrosis in Diabetic Cardiomyopathy via the TGF-β-Smad3 Pathway.

doi: 10.3389/fphar.2021.683335

Figure Lengend Snippet: FIGURE 5 | Overexpression of FST reduces cardiac fibrosis by inhibiting the activation of the TGF-β–Smad3 pathway in vivo and in vitro. Quantitative real-time PCR analysis of TGF-β1, activin A, and TGF-β3 mRNA transcription [(A–C), n≥4] and p-Smad3 and Smad3 protein expression in each group [(D), n 4]. In vitro, NIH3T3 cells were treated with or without high glucose (30 mM), recombinant FST protein (10 ng/ml), and TGF-β1 (20 μM). Protein expression of COL1, COL3, p-Smad3, and Smad3 with different treatments [(E–G), n 3]. *p< 0.05; **p< 0.01; ***p<0.001.

Article Snippet: After starvation in serum-free medium for 24 h, the NIH3T3 cells were incubated in DMEM containing 5.5 mmol/L glucose, 33 mmol/L glucose (high glucose, HG), HG plus 10 ng/ml recombinant FST protein (human recombinant follistatin, BioVision, #4708), or HG plus 10 ng/ml recombinant FST protein and 20 μM TGF-β1 (MedChemExpress, United States).

Techniques: Over Expression, Activation Assay, In Vivo, In Vitro, Real-time Polymerase Chain Reaction, Expressing, Recombinant